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Styrene monomer is a high volume chemical used chiefly in production of poly-
styrene. A clinical survey of 493 production workers was undertaken at the oldest and
largest monomer production, polymerization, and extrusion facility in the U.S. Relative
exposure durations and levels were obtained from occupational histories. Significant
differences between the high and low exposure groups were found with regard to history
of acute p)renarcotic symptoms, acute lower respiratory symptoms, prevalence of
FEV ,/FV < 75%, and elevated GCTP. Other liver function tests, chest x-ray, FVC <
80%, and hematological parameters showed no distinct pattern. A concomitant
mortality study has been mounted and is in progress.
About 2.8 million tons of styrene were pro-
duced in the United States in 1973, slightly
less than toluene and slightly more than vinyl
chloride (1). Polystyrene and styrene polymers
(butadiene-styrene, acryonitritile-butadiene-
styrene for example) production totaled 2.2 mil-
lion tons in 1974 and was expected to rise to 11
millions tons by the year 2000 (2). The other
major use of styrene is as a crosslinking agent
in polyester resin manufacture; 30-40% of the
volume of fresh resin may be styrene (3).
Physically, styrene monomer is a volatile li-
quid (see Table 1); most human exposure is to
this form. During the commonly used hand
layup glass fiber-polyester resin process, evap-
oration rates of styrene are on the order of 50
g/m2 in 30 min; exposures are of the order of
100-200 ppm (3-5) time-weighted average
(TWA) over a several hour period. Levels in
styrene production or polymerization are less
readily obtained. Barcotti (6) gave a level of
192 ppm during polymerization, 25-50 ppm for
other tasks. In addition, heating commercial
polystyrene may give off styrene in amounts up
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to several hundred to a few thousand parts per
million (7,8).
The partition coefficient of styrene favors
steady-state concentrations which are highest
in fat and decrease progressively from fat to
blood to water to air (9,10) (Table 1). Styrene
has been found in the fat of occupationally ex-
posed workers (11).
Table 1. Properties of styrene monomer.
Property
Structure Co
Freezing point, 'C
Boiling point, 'C
Vapor pressure at 25'C, mm Hg
Air saturated with styrene at 250C,
ppm
Vapor density
Explosive limits, ppm
Conversion factor 1 Pr
Water solubility, mg/l.
Miscible in common organic solvents
Partition coefficients:
Water/air
Blood/air
Oil/blood
Oil/air
,H5 -CH = CH2
30.6
145.2
6.1
8026
3.6
11,000-61,000
pm = 4.2 mg/min
300
4.38
32
130
4160
October 1976 171Dynamically, styrene is well absorbed
through the lungs (about 70-90% of that con-
tained in the alveolar ventilation) (12,13).
Over a concentration range of 0-350 ppm and
over a period of several hours, the same pro-
portion of inspired styrene continues to be ab-
sorbed (12). Styrene is also well absorbed
through the skin (14). Blood styrene continues
to rise over time during this period (13,15).
Styrene Styrene
Styrene oxide glycol
0 OH OH
I
R-CH-CH2 -e R-CH-CH2,-* R-CH-CH2 -.
R = COHs-
Styrene oxide has been shown to be a base-
substitution mutagen; other metabolites were
not found to be mutagenic (18). The evidence
for the mutagenicity of styrene itself is most-
ly negative (18); however, Vainio (19) has
stated that styrene may be mutagenic in the
presence of a microsomal system. It may be
that styrene oxide is produced by microsomes.
The metabolism of styrene takes place in the
liver; it is stimulated by phenobarbital and
suppressed by coadministered toluene (20). At
low level styrene exposure (1-50 ppm over
few hours) an increase in mandelic acid excre-
tion in the urine is detectable (4,16,21-23),
peaking about 4-5 hr after a 1-2 hr exposure.
At high level exposure of about 100 ppm TWA
(4, 16), the excretion rate of the metabolites
reaches a plateau. A significant increase in hip-
puric acid excretion occurs (16,24), an obser-
vation first noted for high exposure in 1944
(24). This peak of hippuric acid excretion rate
is delayed for about 20 hr (16).
Toxicology
The toxic effects of styrene were first report-
ed for acute and chronic exposures in 1942
(25). At exposures of 5000 ppm, most animals
were unconsciouis within 1 hr and all died with-
in 8 hr of apparent CNS depression. At ex-
posures of 1300 ppm, a small proportion of
rats and all guinea pigs died after 40 hr of
continuous exposure of pulmonary edema. Acute
Styrene is metabolized in man (about 1%
expired unchanged) to a mixture of hippuric,
phenylgloxylic, and mandelic acids (16) which
are excreted in the urine. The primary meta-
bolic pathway is outlined in eq. (1). Liebman
(17) reviewed the pathway and summarized
the evidence for styrene oxide being the first
metabolic step.
Mandelic Phenylglyoxylic
acid acid
OH 0
l 11
R-CH-COOH o R-C-COOH
R-COOH ) R-C-NH-CH COOH
+ glycine Hippuric
Benzoic acid
acid
+
CO2 1
liver and kidney damage were also noted. At
1300 ppm for 8 hr daily, 5 days per week for
6 months, 10% of guinea pigs died of pulmo-
nary irritation within a few days. Slight in-
crease in weight of liver and kidney was noted
for rats. Eye and nose irritation was common
at 1300 ppm and present at 650 ppm. Hema-
tological values were not altered. Lifetime
studies were not done. Gut (26) found that the
spontaneous motor activity in the rat decreased
at levels of several hundred ppm for 8 hr.
Studies in humans (see Table 2) have found
related effects in acute experiments lasting a
few hours at 800 ppm (24). The subjects were
grossly unsteady and drowsy, with nasal and
eye irritation and a metallic taste in the mouth.
They felt tense and depressed. In the range of
350 ppm irritation was still strong, and ob-
jective tests of coordination and dexterity (15)
and reaction time were abnormal. Gamberale
(27) also found that subjects felt affected and
tense after exposure. At a level of 200 ppm,
Oltramare (13) found increased reaction times
in 30%; Gamberale (27) found no change. Ir-
ritative symptoms were present to 50-100 ppm
(13,15), reaction time increases and subjective
symptoms were inconsistently present (13,15,
27). Odor was noted to levels of 3-5 ppm, but
irritation, increased reaction time, and subjec-
tive symptoms (13) were absent. Acute pul-
monary function changes, or acute liver func-
tion changes have not been systematically ex-
amined in human subjects.
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172Table 2. Toxic effects of styrene in humans.
Number Process Dose,
Reference examined resin/rubber ppm X yr Effects
Barsotti, 1952 41 Monomer manu- 24-196 X years Slight leucopenia, relative lymphocy-
(6) facture, tosis, irritation, decreased night vis-
polymerization ion, urinary hippuric acid normal
Katz, 1962 526 Rubber ca. 20 X years Hepatomegaly (30%), splenomegaly
(33) (6%), increased bilirubin (30%),
leucopenia (30%o), reticulocytosis
(59%)
Zielhuis, 1962 .55 Resin 10-200, up to 5 yr Hematology normal, differential nor-
(3) mal, irritation, drowsiness
Pratt-Johnson, 1964 1 Resin Unknown X 5 yr Retrobulbar neuritis, reverting after
(28) one year, headache, sleepiness, dys-
pepsia
Huzel, 1967 55 Resin 50-100 X yr Weltman reaction 48% Hematology
(5) normal
Benini, 1970 99 Rubber Unknown High red blood count, high siderocytes
(32)
Araki, 1971 1 Resin Unknown X 14 yr Peripheral neuropathy, EMG abnor-
(29) mal, EEG normal, hematology nor-
mal, liver normal, skin atrophy.
Gotell, 1972 12 Resin 100-200 X years Increased reaction time, urine man-
(4) delic acid elevated
Klimokova-Deutskhova, 105 Resin Unknown X years Headache, sleepiness, peripheral neu-
1973 (30) ropathy, EMG, deteriorating EEG,
nystagmus, facial palsy
Chemielewski, 1973 101 Resin Unknown X years Blood protein, lipid normal above av-
(31) erage, glucose tolerance
Oltramare, 1974 5 Resin 20-560 X years 3/5 increased bilirubin, 2/5 wbc below
(13) 5000
Styrene effects have been most widely studied
in the use of polyester resin to make laminates
(glass fiber) or related processes (3,5,13,28-
31). Some have studied copolymer production
in synthetic rubber manufacture (32-33). A
summary of a number of studies is given in
Table 2. Studies of styrene manufacturing and
polymerization factory were reported only by
Barsotti (6) in 1952. He found irritation, es-
pecially of skin and eyes, and complaints of
decreased night vision. A slight leucopenia was
present in some workers, possibly related to the
presence of benzene in the plant. Katz (33)
showed a high prevalence of liver and hema-
tological changes in a synthetic rubber manu-
facturing plant.
Zielhuis (3) in reviewing the literature in
1962, stated that irritation of mucosa and non-
specific asthenia and lassitude were commonly
found associated with industrial exposures to
styrene. Hematological abnormalities were in
Table 3. Sex and age distribution of styrene workers.
Distribution
Age Number %
<21 3 0.6
21-30 104 21.1
31-40 118 23.9
41-50 82 16.6
51-60 107 21.7
61-70 61 12.3
71+ 15 3.0
Unknown 4 0.8
Total 494 100.0
Sex
Male 485 98.2
Female 9 1.8
Total 494 100.0
October 1976 173general not present or were minimal. He notes
that Eastern European authors regard the tox-
icity of styrene as serious, finding abnormalities
in the central nervous system, hematological
system, and liver. Zlobina in 1971 (34) reflect-
ed this continuing concern over low styrene
concentrations.
Current Investigation
A styrene monomer and polymerization plant
was studied, in which a large number of work-
ers had had relatively pure styrene exposure
for many years. This paper reports initial clin-
ical findings in 494 workers. An investigation
of the mortality experience of 563 long-term
styrene workers is also currently underway.
The plant began in 1943 as a production fa-
cility for butadiene and styrene (see Fig. 1),
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FIGURE 2. Current styrene production.
product of the ethylbenzene-styrene conversion
process. About 650 workers are employed in
production. Approximate numbers employed in
each area are noted in Figure 2, e.g., about 20
workers are involved in storage of ethylben-
zene, 200 in conversion of 99%o + pure styrene
to polystyrene. Most of the end product is poly-
styrene beads (polystyrene impregnated with
various pentanes). When the "beads" are heat-
ed and extruded, they expand to polystyrene
foam used for coffee cups and other articles.
Off-quality beads are processed at the plant to
foam trays, used primarily in the retail pack-
aging of meat.
FIGURE 1. Plant history.
manufacturing the monomers but not copoly-
merizing them. Butadiene was produced until
about 1950. Styrene and butadiene were poly-
merized elsewhere into butadiene rubber. Since
the 1950's the principal product has been poly-
styrene. Limited extrusion of polystyrene also
is undertaken; the remainder of the polysty-
rene is extruded elsewhere. Over 90% of the
polystyrene coffee cups in the United States
comes from polystyrene manufactured in this
plant. Since 1969 ethylbenzene has been the
starting product. Little benzene has been pres-
ent and that in specific areas, notably the ben-
zene building and styrene monomer purification
areas (see Fig. 2). Significantly less benzene
exposure occurred during the 1963-1975 period.
Some toluene is recovered, primarily as a side
Characteristics of Group
The group examined numbered 494. The me-
dian age was in the 40's, but because of hiring
practices in the past, the distribution is bi-
modal (see Table 3). Males constituted 98%
of the group. Table 4 shows in which year each
of the workers was first employed. Relatively
few workers were first employed in the late
1950's and early 1960's.
Table 4. Year of first exposure of styrene workers.
Distribution
Year Number t
<1950 112 22.7
1950-54 94 19.0
1955-59 25 5.1
1960-64 7 1.4
1965-69 109 22.1
1970+ 147 29.8
Total 494 100.0
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Proportion done;
Test information selection Purpose Organ system
Basic demographic data (age, sex,
height, weight)
Blood chemistries (25)
CEA
Styrene
Urine, protein, glucose
Urine, mandelic, phenylglyoxidic,
and hippuric acid
Sputum, cytology
Occupational history (complete
lifetime history up to last shift
worked)
Medical history
Respiratory history, standard
questionnaire
Special questionnaire, acute symp-
toms
Physical examination
Ophthalmological examination
Chest x-ray
Spirometry
Codiffusion
Reaction time
Nerve conduction velocity
Fat aspiration
Hemogram, platelets
Urine, mutagenic
Chromosome morphology
All Standardization of tests, particularly
pulmonary function
All Routine screen; special emphasis on
liver
All To select those with higher possibility
for developing carcinoma
All Test system for detection of styrene in
low blood concentration; possible val-
idation of occupational history cate-
gories
All Routine screen
All
All smokers plus
nonsmokers over
40
All
All
All
All
All
Styrene metabolites, test of methol-
ogy; possible validation of occupa-
tional history categories
Screen for increased atypia and malig-
nancy
Determine specific exposure; last shift
history to be related to urine meta-
bolite levels
Elimination of effects caused by known
medical conditions
Enables other variables to be controlled
for cigarette smoking
Possible acute symptoms related to
styrene-irritative, prenarcotic
Chest, abdomen, peripheral nervous
system especially
All Screening exam; external examination
All General screen; ILO U/C pneumoco-
niosis reading
All FEV, FVC, flow at 25% of volume,
FEF (25-75%)
60 unselected CO diffusing capacity, single breath
Unselected
100 selected
25 selected
All
30 selected
10 selected
Simple reaction time
Multiple conductions, lower and upper
extremities
Fat level of styrene, ethylbenzene,
toluene
See if abnormality relates to benzene
or styrene areas
Possible effect on genetic material
Possible effect on genetic material
Liver
Lung, liver, other
malignancy
Kidney,
endocrine
Lung
Cardiopulmonary
Eye, ENT, res-
piratory CNS
Nervous system,
liver, spleen,
pulmonary,
ENT
Eye
Lung, heart
Lung
Lung
Nervous system
Peripheral nerv-
ous system
Hematological
DNA
DNA
Studies Undertaken
Table 5 summarizes the information ga-
thered during this examination. Selection was
governed by trying to achieve clinical breadth
while also trying to test hypotheses gleaned
from literature review and from interviewing
workers and management personnel prior to
the examination. It is evident that the scien-
tific emphasis of this survey was upon hypoth-
esis development rather than hypothesis test-
ing.
October 1976 175This report will deal with prevalence of cer-
tain symptoms (prenarcosis, acute irritation,
those of chronic bronchitis) and test results
(simple spirometry, chest x-ray, serum liver
enzymes, hemogram, and platelet count). The
above parameters will be related to estimated
styrene exposure.
From review of job descriptions and actual
tasks performed by those in each job, an esti-
mate of relative exposure was obtained (see
Table 6). In developing this estimate, we uti-
lized the experience of management and of
workers and had available a NIOSH Health
Hazard Evaluation (35) of the facility. Of the
488 production and maintenance members for
which adequate occupational histories are avail-
able, 200 were judged currently to be in low
exposure, and 288 in relatively high styrene
exposure. Significant benzene exposure was
thought to be a possibility in certain job cate-
gories, as marked. Analysis is by relative ex-
posure and time. High exposure is defined as
80% or more of years having been spent in a
high exposure job. The level of 90%o has been
used as the dividing line for history of acute
symptoms.
Results
Styrene at high concentrations (hundreds of
ppm) produces a prenarcotic syndrome, de-
scribed by the individual affected as being
"lightheaded" or "drunk." An attempt was
made to exclude prenarcosis due to other sub-
stances (such as pentane) which also cause the
syndrome. Of the workers 13% overall had
had at least one episode of prenarcosis (see
Table 7). Those with high styrene exposure
had significantly more prenarcosis than those
with low exposure.
Table 6. Occupational distribution of high and low
styrene exposure.
Distribution,
no.
Low exposure (total 200)
Retired or working elsewhere
Power house
Handling of extruded polystyrene or
finished beads
Sheet plant
Polystyrene handler
Packaging operator
Handling and transportation, miscel-
laneous packaged materials
Maintenance, low exposure
Other
High exposure (total 288)
Production:
Styrene manufacture
Styrene purification a
Styrene polymerization
To polystyrene
To copolymers, special processes a
Miscellaneous production workers a
Polystyrene extrusion
Maintenance:
Pipe fitters a
Millwrights a
Electrician
Laborer
Welder
Other
Other high exposure a
41
22
41
16
25
22
22
11
16
14
70
38
25
14
29
19
15
13
11
20
4
Table 7. Acute prenarcotic symptoms in styrene-
exposed workers.
History of prenarcotic symptoms a
Styrene 0.1-7.0 7.1-20 >20.0
exposure yr yr yr Total
Low 15/143 2/61 13/102 30/306
(10%0) (3.3%) (13%) (10%)
High 3/34 11/53 20/95 34/182
(9%) (21%) (21%) (19%)
Total 18/177 13/144 33/197 64/488
(l1o0) (11%) (17%) (13%)
a Significance for high as compared with low: x2 =
7.81, 0.001 <p <0.01; x2 = 0.08, NS (0.1-7.0 yr);
x2 =8.57, 0.001 <p <0.01 (7.0-20.0 yr); x2 = 2.43, NS
(>20.0 yr).
Acute mucous membrane irritation is a com-
mon occurrence above levels of 50-100 ppm in
experimental work with subjects never before
exposed to styrene. Significant tolerance may
develop in industrial populations. This fact may
explain our failure to find differences in pre-
valence between relatively high and low styrene
(see Table 8).
The workers were also asked if they ever
had wheezing or tightness in the chest from
styrene vapors. In this case 11%o of workers
had such an episode. Significantly more high
than low exposed workers had had this symp-
tom (see Table 9).
Environmental Health Perspectives
a Significant benzene exposure possible.
176Table 8. Mucous membrane irritation in styrene-exposed
workers.
History of mucous membrane irritation
Styrene 0.1-7.0 7.1-20 >20.0
exposure yr yr yr Total
Low 28/143 6/61 17/102 51/306
(20%) (10%) (17%) (17%)
High 4/34 11/53 22/95 37/182
(12%) (21%) (23%) (20% )
Total 32/177 17/114 39/197 88/488
(18% ) (15%) (20%) (18%)
Table 9. Acute lower respiratory symptoms in styrene-
exposed workers.
History of acute lower respiratory
symptoms a
Styrene 0.1-7.0 7.1-20 >20.0
exposure yr yr yr Total
Low 9/143 5/61 8/102 22/306
(6.3%) (8%) (8%7o) (7.2%o)
High 4/34 13/53 17/95 34/182
(12%) (25%) (18%) (19% )
Total 13/177 18/114 25/197 56/488
(7%) (16%) (13%) (11%)
a Significance for low compared with high: x2 =
14.84, p <0.001 (overall); x2= 1.21 NS (0.1-7 yr);
x 2=5.69, 0.01 <p <0.02 (7.1-20.0 yr); X2=4.49, 0.02
<p <0.05 (>20.0 yr).
The same pattern is present for recurrent
symptoms, i.e., present weekly to monthly over
a period of time (see Table 10) ; 12.1% of the
workers in the high styrene area versus 4.9%
of those in low-styrene exposures had recur-
rent episodes.
Table 10. Recurrent acute lower respiratory symptoms
in styrene-exposed workers.
History of recurrent lower respiratory
symptoms a
Styrene 0.1-7.0 7.1-20 >20.0
exposure yr yr yr Total
Low 6/143 3/61 6/102 15/306
(4.2%) (4.9%) (5.9%) (4.9%)
High 2/34 8/53 12/95 22/182
(5.9%) (15%) (13%) (12.1%)
Total 8/177 11/114 18/197 37/488
(4.5%) (9.6%) (9.1%) (7.6% )
a Significance for low styrene exposure as compared
with high styrene exposure: x2 = 8.41, 0.001 <p <0.01.
The prevalence of chronic bronchitis was in-
vestigated (see Table 11); 19% of the workers
reported such symptoms.
Table 11. Chronic bronchitis in styrene-exposed
workers.
Prevalence of chronic bronchitis a
Styrene 0.1-7.0 7.1-20 >20.0
exposure yr yr yr Total
Low 6/83 7/61 22/78 35/222
(7.2%) (11%) (28%) (16%)
High 9/61 17/70 28/119 54/250
(15%) (24%) (24%) (22%)
Total 15/144 24/131 50/197 89/472
(10%) (18%) (25%) (19%)
a Definition: cough and sputum production on most
days for at least 3 months for at least 2 yr.
To eliminate the effect of smoking, non-
smokers were analyzed separately (see Table
12). Of the nonsmokers, 6% had symptoms
consistent with chronic bronchitis. No trends
were noted. We have seen such findings in other
industrial populations. It is questionable
whether styrene exposure had etiological im-
portance in this population.
Table 12. Chronic bronchitis in nonsmoking styrene-
exposed-workers.
Prevalence of chronic bronchitis in
nonsmokers a
Styrene 0.1-7.0 7.1-20 >20.0
exposure yr yr yr Total
Low 2/19 2/18 0/13 4/50
(11%) (11%) (0%) (8%)
High 1/15 0/15 0/23 1/53
(7%) (0%) (0%) (2%)
Total 3/34 2/33 0/36 5/103
(9%) (6%) (0%) (5%)
a Definition: cough and sputum production on most
days for at least 3 months for at least 2 years.
The prevalence of airway obstruction defined
as FEV1/FVC < 75% was also investigated
(see Table 13). Overall, 35.3% satisfied this
criteria for obstruction; here, the high and low
styrene groups were statistically different. Of
the nonsmokers, 31.6%) had evidence of air-
ways obstruction (see Table 14), although no
October 1976 177pattern consistent with a simple dose-response
relationship was present. As expected, obstruc-
tion increased with years on the job among
smokers (see Table 15). Overall, 5.9%' of the
men had FVC < 80% predicted (see Table
16); restriction was not of significance in this
group of workers.
Table 13. Airway obstruction (FEV,/FVC < 75%) in
styrene-exposed workers.a
Prevalence of airway obstruction b
Styrene 0.1-7.0 7.1-20 >20.0
exposure yr yr yr Total
Low 17/82 18/60 36/72 71/214
(21%) (30%) (50%) (33%)
High 15/60 27/69 50/108 92/237
(25%) (39%) (46%) (39%)
Total 32/142 45/129 86/180 163/451
(23%) (35%) (46%) (35.2%)
a FEV-forced expiratory volume at 1 sec; FVC-
forced vital capacity.
b Significance for low styrene exposure as compared
with high styrene exposure: X= 2.17, not significant
(NS).
Table 14. Airway obstruction (FEV,/FVC < 75%) in
nonsmoking styrene-exposed workers.
Prevalence of airway obstruction a
Styrene 0.1-7.0 7.1-20 >20.0
exposure yr yr yr Total
Low 5/19 6/18 7/13 18/50
(26%) (33%) (54%) (36%)
High 5/15 3/15 5/23 13/53
(33%) (20%) (22%) (25%)
Total 10/34 9/33 12/36 31/103
(29%) (27%) (33%) (30%)
a Significance for low styrene exposure as compared
with high styrene exposure: = 1.46 (NS).
Table 15. Airway obstruction (FEV,/FVC < 75%) in
smoking styrene-exposed workers.
Prevalence of airway obstruction a
Styrene 0.1-7.0 7.1-20 >20.0
exposure yr yr yr Total
Low 8/49 10/29 21/34 39/112
(16%) (34%) (62%) (35%)
High 8/40 17/43 21/41 46/124
(20%) (40%) (51%) (37%)
Total 16/89 27/72 42/75 85/236
(18%) (38%) (566%) (36%)
a Significance for low styrene exposure as compared
with high styrene exposure: = 0.13 (NS).
Table 16. Restriction (FVC < 80% predicted) in
styrene-exposed workers.
Prevalence of restriction
Styrene 0.1-7.0 7.1-20 >20.0
exposure yr yr yr Total
Low 3/82 4/60 5/72 12/214
(3.7%) (6.7%) (6.9%) (5.6%)
High 1/60 1/69 5/108 7/237
(1.7%) (1.4%) (4.6%) (2.9%)
Total 4/142 5/129 10/180 19/451
(2.8%) (3.9%) (5.6%) (4.2%)
The x-rays were categorized by the ILO-U/C
International Classification of Radiographs of
Pneumoconiosis (see Table 17). Apart from
those with history of previous coal or asbestos
exposure there was no finding of significant
radiological change; surely not at the level
we have seen in vinyl chloride workers (31).
Table 17. Abnormal x-ray findings among styrene-
exposed workers.a
ILO U/C classification
Styrene
exposure 1/0-1/2 2/1-2/3 3/2-3/4 Total
Low 17/250 5/250 1/250 23/250
(6.8%o) (2.0%) (0.4% ) (9.2%)
High 14/167 4/167 0/167 18/167
(8.4%) (2.4%) (0%) (11%)
Total 31/417 9/417 1/417 41/417
(7.4%) (2.2%) (0.21%) (9.8%)
a Excluding those
bestos or coal dust.
with known prior exposure to as-
Hepatic function was investigated by using
bilirubin, alkaline phosphatase, SGPT, GGTP,
and SGOT as parameters (see Table 18). The
distribution of the abnormal results was in-
vestigated. For this initial analysis, "abnormal"
was defined as at or above the 96th percentile
as compared with a group of 993 nonhospital-
ized men aged 40-44 tested at the same lab-
oratory; 471 sets of results were available for
analysis.
When tested for styrene (high and low) and
duration, only GGTP showed a nonrandom pat-
tern (see Table 19). Overall, 4.9%o were ele-
vated: 6.7% in the high styrene and 2.8% in
the low styrene groups. This difference was
statistically significant. The difference shown
Environmental Health Perspectives 178Table 18. Liver function tests on 471 styrene-exposed
workers.
"Positives" a
No. %
Bilirubin 1.0 mg %o 15 3.2%
Alkaline phosphatase
- 41 units 28 5.9%
SGPT 70 I.U. 19 4.0%
GGTP 45 I.U. 23 4.9%
SGOT 50 I.U. 16 3.4%
a Defined as 96th percentile or higher as compared
with a group of 993 nonhospitalized men aged 40-44,
done at same laboratory.
in the > 20 and < 20 yr groups is significant
but needs to be adjusted for age-dependent in-
crease in GGTP. When those with alcohol con-
sumptions of more than 400 proof ounces (2 oz
pure ethanol) per week are excluded (see Table
20), the differences increase between the low
and high styrene groups. For those currently
working, those with low styrene and high sty-
rene with concurrent relatively low and high
benzene are compared (see Table 21). No com-
parisons reach statistical significance, although
both chemicals may have an effect on the pre-
valence of GGTP. No other patterns were ob-
served when we analyzed other liver function
tests in a similar manner.
Table 19. Elevated GGTP in styrene-exposed workers.
Incidence of elevated GGTP a
Styrene 0.1-7.0 7.1-20 >20.0
exposure yr yr yr Total
Low 1/83 1/60 4/75 6/218
(1.2%) (1.7%) (5.3%) (2.8%)
High 1/62 2/72 14/119 17/253
(1.6%) (2.8%) (12%) (6.7%)
Total 2/145 3/132 18/194 23/471
(1.4%) (2.3%l) (9.3%) (4.9%)
a Significance for high styrene compared with low
styrene: x2 = 3.93, 0.02 <p 0.05; for over 20 yr com-
pared with under 20 yr: x2 = 13.72, p <0.001.
Hematological parameters investigated in-
cluded hemoglobin, white blood count, and
platelet count (see Table 22): 13.6% of the
workers had hemoglobin levels below 14.0 g-%;
2.7%c had white blood counts below 4800; and
7.4% had platelet counts below 180,000. An-
Table 20. Elevated GGTP in styrene exposed workers
with low alcohol intake.a
Incidence of elevated GGTP b
Styrene 0.1-7.0 7.1-20 >20.0
exposure yr yr yr Total
Low 0/68 1/53 2/56 3/177
(0%) (1.9%) (3.6%) (1.7% )
High 1/52 2/60 12/96 15/208
(1.9%) (3.3%o) (13%) (7.2%o)
Total 1/120 3/113 14/152 18/385
(0.8%) (2.7%o) (9.2%) (4.7% )
a Workers consuming :400 proof ounces/week alco-
hol excluded.
b Significance for high styrene compared with low
styrene: x2 = 6.53, 0.01 <p <0.02; for over 20 yr com-
pared with under 20 yr: x2 = 11.59, p <0.001.
Table 21. Elevated GGTP of styrene-exposed workers
currently working.a
Incidence of elevated GGTPb
Styrene Low benzene High benzene
exposure exposure exposure Total
Low 4/161 4/161
(2.5%) (2.5%Olo)
High 7/132 6/109 13/241
(5.3%) (5.5%) (5.4%)
Total 11/293 6/109 17/402
(3.8%) (5.5%) (4.2%)
a Workers consuming :400 proof ounces/week alco-
hol excluded.
b No significant differences.
alyses similar to that performed on the liver
function results showed random distribution of
the abnormalities.
Over 300 fundal examinations were made by
an opthalmologist. No optic neuritis or other
unexplained fundal abnormalities were noted.
A case report (28) of possible association be-
tween styrene and optic neuritis has been pub-
lished. Analysis of the remaining tests will be
reported later.
Table 22. Hematological parameters in styrene-exposed
workers.
Positive
Parameter No. 0
Hemoglobin <14.0 g-% 66/486 13.6
White blood count <4800 13/486 2.7
Platelet count <180,000 36/486 7.4
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The results of this clinical survey confirm
styrene to be an irritant of the mucous mem-
branes of the upper respiratory tract. The
possibility that styrene may also be a signifi-
cant lower respiratory irritant in occupational
groups must also be considered. That 30% of
the nonsmokers had FEV1/FVC < 75%, and
that 12%o of the high exposed workers (com-
pared to 4%o of the lower exposed) had re-
peated episodes of wheezing and/or tightness
in the chest suggests an etiological relationship.
Serum y-glutanyl transpeptidase was higher
among those with higher exposure, consistent
with hepatic changes. Hematological findings
did not yield evidence of significant marrow
depression in this preliminary analysis.
In comparison with findings of studies (36,
37) done in a similar manner of workers ex-
posed to another monomer, vinyl chloride, there
was no evidence of characteristic vinyl chloride
monomer changes such as Reynaud's syndrome,
acroosteolysis, clinical hepatic disfunction, or
skin changes No overt neoplasms were found
in this survey.
Summary
Initial analysis of findings in a clinical sur-
vey of 494 workers at a styrene manufacturing,
polymerization, and polystyrene extrusion fa-
cility has been undertaken. No unusual clinical
patterns emerged, although styrene monomer is
confirmed as an irritant and CNS depressant,
and some changes in pulmonary function and in
serum GGTP were found. An investigation of
the mortality experience of workers at this
facility is underway and will be reported later,
as will findings of other studies performed
during this survey of styrene-exposed workers.
This work was supported by NIEHS Center Grant
ES 00928 and by Research Training Grant HL 03591-01
(W. V. Lorimer).
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